SciClone Pharmaceuticals, Inc. (SCLN) Files S-3 Registration Statement Prospectus Supplement Related to Sigma-Tau Group Transaction
4/30/2012 8:49:39 AM
More...
|
Dyax Corp. (DYAX) and Sigma-Tau Group Expand Agreement to Commercialize KALBITOR(R) (ecallantide) for Hereditary Angioedema
1/12/2011 10:16:40 AM
More...
|
Dyax Corp. (DYAX) and Sigma-Tau Group Expand Agreement to Commercialize KALBITOR(R) (ecallantide) for Hereditary Angioedema
1/11/2011 10:58:48 AM
More...
|
Enzon Pharmaceuticals, Inc. (ENZN) Stockholders Approve Sale of Specialty Pharmaceutical Business to Sigma-Tau Group
1/28/2010 9:05:14 AM
More...
|
SciClone Pharmaceuticals, Inc. (SCLN) and Sigma-Tau Group Announce Positive Preliminary Results in Clinical Study Examining ZADAXIN'S Ability to Enhance Response to H1N1 Vaccine
1/12/2010 11:40:59 AM
More...
|
Gentium S.p.A. Announces Extension of License and Supply and Cost Sharing Agreements with Sigma-Tau Group
1/11/2010 9:42:03 AM
More...
|
SciClone Pharmaceuticals, Inc. (SCLN) Announces Commencement and Complete Enrollment of Clinical Study Examining ZADAXIN's Ability to Enhance the H1N1 Vaccine Led by European Partner, Sigma-Tau Group
12/1/2009 11:20:40 AM
More...
|
Enzon Pharmaceuticals, Inc. (ENZN) to Sell Specialty Pharmaceuticals Business to the Sigma-Tau Group for $300 Million Plus up to $27 Million
11/9/2009 7:47:07 AM
More...
|